Ken Suzawa Selected Research

Ken Suzawa Research Topics

Disease

22	Neoplasms (Cancer) 01/2022 - 03/2014
18	Lung Neoplasms (Lung Cancer) 01/2022 - 03/2015
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2021 - 01/2014
4	Neoplasm Metastasis (Metastasis) 04/2022 - 01/2018
4	Breast Neoplasms (Breast Cancer) 11/2021 - 01/2017
3	Sarcoma (Soft Tissue Sarcoma) 04/2022 - 01/2021
2	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2022 - 01/2021
2	Lung Injury 10/2021 - 01/2021
1	Bronchiolitis Obliterans Syndrome 02/2022
1	Lymphatic Metastasis 01/2022
1	Ischemia 10/2021
1	Reperfusion Injury 10/2021
1	Castleman Disease (Castleman's Disease) 09/2021
1	Fistula 02/2021
1	Idiopathic Pulmonary Fibrosis 01/2021
1	Persistent Infection 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2021
1	Pulmonary Aspergillosis 08/2020
1	Radiation Pneumonitis 08/2020
1	Adenocarcinoma of Lung 01/2020
1	Disease Progression 07/2019
1	Infections 10/2018
1	Primary Graft Dysfunction 10/2018
1	Leukemia 01/2018
1	Mesothelioma 12/2016
1	Malignant Mesothelioma 01/2016
1	Chylothorax 04/2015
1	Pneumocephalus 04/2015
1	Paraganglioma (Paragangliomas) 03/2014

Drug/Important Bio-Agent (IBA)

12	Tyrosine Kinase InhibitorsIBA 03/2020 - 03/2015
5	human ERBB2 proteinIBA 11/2021 - 01/2017
5	ErbB Receptors (EGF Receptor)IBA 04/2019 - 03/2015
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2016
4	Pharmaceutical PreparationsIBA 03/2020 - 01/2017
4	AfatinibIBA 05/2018 - 10/2015
3	Messenger RNA (mRNA)IBA 01/2022 - 01/2017
2	Trastuzumab (Herceptin)FDA Link 11/2021 - 01/2017
2	Monoclonal AntibodiesIBA 10/2021 - 09/2021
2	Carrier Proteins (Binding Protein)IBA 10/2021 - 12/2016
2	Phosphotransferases (Kinase)IBA 12/2020 - 01/2018
2	neratinibIBA 03/2020 - 03/2019
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 12/2016
1	Keratin-19 (Keratin 19)IBA 01/2022
1	Nucleic AcidsIBA 01/2022
1	Ado-Trastuzumab EmtansineIBA 11/2021
1	HMGB1 Protein (HMG1)IBA 10/2021
1	HMGB ProteinsIBA 10/2021
1	Mitogen-Activated Protein KinasesIBA 10/2021
1	ChemokinesIBA 10/2021
1	salicylhydroxamic acid (SHAM)IBA 10/2021
1	ChromatinIBA 10/2021
1	CytokinesIBA 10/2021
1	Interleukin-6 (Interleukin 6)IBA 09/2021
1	EnbucrilateIBA 02/2021
1	indium-bleomycinIBA 01/2021
1	Dihydrotachysterol (AT 10)IBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	IsoflavonesIBA 01/2021
1	Tamoxifen FDA LinkGeneric 01/2021
1	Neutralizing AntibodiesIBA 01/2021
1	EquolIBA 01/2021
1	agerafenibIBA 12/2020
1	cabozantinibIBA 12/2020
1	LY3009120IBA 05/2020
1	Dasatinib (BMS 354825)FDA Link 03/2020
1	Monensin (Coban)IBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	STA 9090IBA 04/2019
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 04/2019
1	Cell-Free Nucleic AcidsIBA 10/2018
1	Biomarkers (Surrogate Marker)IBA 10/2018
1	DNA (Deoxyribonucleic Acid)IBA 10/2018
1	Docetaxel (Taxotere)FDA Link 10/2017
1	ElacridarIBA 10/2017
1	Therapeutic UsesIBA 01/2017
1	Histocompatibility Antigens Class IIBA 01/2017
1	Lapatinib (GW572016)FDA Link 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 12/2016
1	Biological ProductsIBA 01/2016
1	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 03/2015
1	CatecholaminesIBA 03/2014

Therapy/Procedure

13	Therapeutics 09/2021 - 01/2016
6	Chemoradiotherapy 09/2021 - 04/2015
3	Metastasectomy 04/2022 - 01/2021
3	Lung Transplantation 02/2022 - 10/2018
2	Adjuvant Chemotherapy 09/2021 - 08/2020
1	Mechanical Ventilators (Ventilator) 11/2022
1	Intravenous Administration 10/2021
1	Pneumonectomy (Lung Volume Reduction) 02/2021
1	Molecular Targeted Therapy 03/2020
1	Heavy Ion Radiotherapy 01/2014